50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
'Crucial' vote could move Italy to right; many might boycott
China using civilian ships to enhance navy capability, reach
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
'Crucial' vote could move Italy to right; many might boycott
China using civilian ships to enhance navy capability, reach
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
'Crucial' vote could move Italy to right; many might boycott
China using civilian ships to enhance navy capability, reach
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
'Crucial' vote could move Italy to right; many might boycott
China using civilian ships to enhance navy capability, reach
NASDAQ:EYPT

EyePoint Pharmaceuticals - EYPT Stock Forecast, Price & News

$7.20
-0.03 (-0.41%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.94
$7.25
50-Day Range
$7.20
$11.12
52-Week Range
$6.94
$21.50
Volume
122,332 shs
Average Volume
125,187 shs
Market Capitalization
$245.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.00

EyePoint Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
275.0% Upside
$27.00 Price Target
Short Interest
Bearish
7.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.43) to ($2.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.76 out of 5 stars

Medical Sector

860th out of 1,080 stocks

Analytical Instruments Industry

26th out of 29 stocks

EYPT stock logo

About EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EYPT Stock News Headlines

See More Headlines
Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EYPT Company Calendar

Last Earnings
11/03/2021
Today
9/24/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EYPT
Employees
122
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$27.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+275.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-58,420,000.00
Net Margins
-186.14%
Pretax Margin
-186.14%

Debt

Sales & Book Value

Annual Sales
$35.31 million
Book Value
$5.44 per share

Miscellaneous

Free Float
26,065,000
Market Cap
$245.30 million
Optionable
Optionable
Beta
1.21

Social Links


Key Executives

  • Ms. Nancy S. Lurker (Age 65)
    Pres, CEO & Director
    Comp: $1.11M
  • Mr. George O. Elston (Age 57)
    Chief Financial Officer
    Comp: $743.86k
  • Dr. Jay S. Duker M.D. (Age 63)
    Chief Operating Officer
    Comp: $614.96k
  • Mr. David Scott Jones (Age 55)
    Sr. VP & Chief Commercial Officer
    Comp: $672.08k
  • Mr. Said Saim (Age 64)
    Chief Technology Officer
  • Mr. Ron I. Honig Esq.
    Chief Legal Officer & Company Sec.
  • Mr. Michael Pine (Age 46)
    Chief Corp. Devel. & Strategy Officer
  • Ms. Jennifer Leonard
    Chief People Officer & Sr. VP of IT
  • Dr. Dario A. Paggiarino (Age 65)
    Sr. VP & Chief Medical Officer
  • Ms. Isabelle Lefebvre
    Chief Regulatory Officer













EYPT Stock - Frequently Asked Questions

Should I buy or sell EyePoint Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EYPT shares.
View EYPT analyst ratings
or view top-rated stocks.

What is EyePoint Pharmaceuticals' stock price forecast for 2022?

4 Wall Street research analysts have issued 1 year target prices for EyePoint Pharmaceuticals' shares. Their EYPT share price forecasts range from $21.00 to $35.00. On average, they predict the company's stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 275.0% from the stock's current price.
View analysts price targets for EYPT
or view top-rated stocks among Wall Street analysts.

How have EYPT shares performed in 2022?

EyePoint Pharmaceuticals' stock was trading at $12.24 at the start of the year. Since then, EYPT shares have decreased by 41.2% and is now trading at $7.20.
View the best growth stocks for 2022 here
.

When is EyePoint Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our EYPT earnings forecast
.

How were EyePoint Pharmaceuticals' earnings last quarter?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) posted its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.11. The business earned $9.06 million during the quarter, compared to the consensus estimate of $9.60 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 50.36% and a negative net margin of 186.14%. During the same period in the prior year, the business earned ($0.30) EPS.

When did EyePoint Pharmaceuticals' stock split?

EyePoint Pharmaceuticals's stock reverse split on the morning of Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of EyePoint Pharmaceuticals own?
What is EyePoint Pharmaceuticals' stock symbol?

EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

Who are EyePoint Pharmaceuticals' major shareholders?

EyePoint Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (16.00%), Point72 Asset Management L.P. (3.58%), Goldman Sachs Group Inc. (2.61%), Verition Fund Management LLC (1.58%), State Street Corp (1.19%) and Millennium Management LLC (1.01%). Insiders that own company stock include George Elston and Nancy Lurker.
View institutional ownership trends
.

How do I buy shares of EyePoint Pharmaceuticals?

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is EyePoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $7.20.

How much money does EyePoint Pharmaceuticals make?

EyePoint Pharmaceuticals (NASDAQ:EYPT) has a market capitalization of $245.30 million and generates $35.31 million in revenue each year. The company earns $-58,420,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis.

How many employees does EyePoint Pharmaceuticals have?

The company employs 122 workers across the globe.

How can I contact EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The official website for the company is eyepointpharma.com. The company can be reached via phone at (617) 926-5000, via email at eyepoint@argotpartners.com, or via fax at 617-926-5050.

This page (NASDAQ:EYPT) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.